Quick Answer
Vera Therapeutics, Inc. reported Research And Development Expense of $215.26 million for the year ending 2025.
- Vera Therapeutics, Inc. showed an increase of +70.6% in Research And Development Expense from 2024 to 2025.
- This data is from Vera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $1.44 million | Q2 2020: $1.95 million | Q3 2020: $1.97 million | Q1 2021: $2.93 million | Q2 2021: $3.24 million | Q3 2021: $3.56 million | Q1 2022: $12.55 million | Q2 2022: $10.11 million | Q3 2022: $19.66 million | Q1 2023: $25.11 million | Q2 2023: $16.23 million | Q3 2023: $16.10 million | Q1 2024: $23.20 million | Q2 2024: $29.31 million | Q3 2024: $40.31 million | Q1 2025: $41.28 million | Q2 2025: $58.20 million | Q3 2025: $56.47 million.
- Over the full 6 years of available data (2020 to 2025), Vera Therapeutics, Inc.'s Research And Development Expense has grown by 376.2%.
- Historical annual values: Fiscal year 2025: $215.26 million | Fiscal year 2024: $126.17 million | Fiscal year 2023: $78.23 million | Fiscal year 2022: $68.99 million | Fiscal year 2021: $22.48 million | Fiscal year 2020: $45.21 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: